-
Ultragenyx Discontinues Phase 3 GNE Myopathy Study
Wednesday, August 23, 2017 - 11:22am | 391Read More...Shares of Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) tumbled more than 12 percent Wednesday after the company offered a disappointing update concerning a muscle-disease drug study. The biopharmaceutical company, which focuses on the development of novel products for rare and ultra-rare diseases,...
-
Baird Buying Ultragenyx And BioMarin
Tuesday, March 8, 2016 - 2:54pm | 542Read More...Baird has initiated coverage on Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) with an Outperform rating, citing diversified pipeline with multiple near-term catalysts. It also upgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to Outperform with a $110 price target. Ultragenyx Ultragenyx's...
